Trials
| (6 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) | |||
| Zeile 1: | Zeile 1: | ||
{{pnc}} | {{pnc}} | ||
*[https://clinicaltrials.gov/ct2/results?cond=COVID-19 at clinicaltrials.gov 1323 running] | *[https://clinicaltrials.gov/ct2/results?cond=COVID-19 at clinicaltrials.gov 1323 running] | ||
| + | {{tp|p=32562594|t=2020. Pregnant Women in Trials of COVID-19: A Critical Time to Consider Ethical Frameworks of Inclusion in Clinical Trials.|pdf=|usr=010}} | ||
| + | {{tp|p=C7102592|t=ä. Core Outcome Set for Clinical Trials on Coronavirus Disease 2019 (COS-COVID) |pdf=|usr=}} | ||
| + | {{tp|p=32588335|t=2020. COVID-19, equipoise and observational studies: a reminder of forgotten issues.|pdf=|usr=010}} | ||
| + | {{tp|p=32290293|t=2020. A Review of SARS-CoV-2 and the Ongoing Clinical Trials |pdf=|usr=}} | ||
| + | {{tp|p=32363333|t=ä. A real-time dashboard of clinical trials for COVID-19 |pdf=|usr=}} | ||
| + | {{tp|p=32567239|t=2020. Advantages of Using Lotteries to Select Participants for High-Demand Covid-19 Treatment Trials.|pdf=|usr=010}} | ||
| + | {{ttp|p=C7156793|t=2020. COVID-19 randomised trial protocols: rapid publication without barriers |pdf=|usr=}} | ||
| + | {{tp|p=32292826|t=2020. A living systematic review protocol for COVID-19 clinical trial registrations |pdf=|usr=}} | ||
| + | {{tp|p=32566569|t=2020. Appealing for efficient, well organized clinical trials on COVID-19.|pdf=|usr=011}} | ||
| + | {{tp|p=32245769|t=2020. Managing clinical trials for covid-19: the importance of ethics committees |pdf=|usr=}} | ||
| + | {{tp|p=32532425|t=2020. Inclusion of pregnant women in clinical trials of COVID-19 therapies: what have we learned?|pdf=|usr=011}} | ||
| + | {{tp|p=32379296|t=2020. Inclusion of Children in Clinical Trials of Treatments for Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}} | ||
| + | {{tp|p=32341581|t=2020. Antibody testing will enhance the power and accuracy of COVID-19-prevention trials |pdf=|usr=}} | ||
| + | {{tp|p=32179860|t=2020. Don t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees |pdf=|usr=}} | ||
| + | {{tp|p=32349053|t=ä. Protection by Exclusion: Another Missed Opportunity to Include Pregnant Women in Research During the Coronavirus Disease 2019 (COVID-19) Pandemic |pdf=|usr=}} | ||
| + | {{tp|p=32369865|t=2020. Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic |pdf=|usr=}} | ||
| + | {{tp|p=32333712|t=2020. SARS-CoV-2 pandemic and the need for transplant-oriented trials |pdf=|usr=}} | ||
| + | {{tp|p=32294824|t=2020. An urgent call for raising the scientific rigorousness of clinical trials on COVID-19 |pdf=|usr=}} | ||
| + | {{tp|p=32610153|t=2020. COVID-19 trials in Italy: A call for simplicity, top standards and global pooling.|pdf=|usr=011}} | ||
| + | {{tp|p=32292626|t=ä. Core Outcome Set for Clinical Trials on Coronavirus Disease 2019 (COS-COVID) |pdf=|usr=}} | ||
| + | {{tp|p=C7156793|t=2020. COVID-19 randomised trial protocols: rapid publication without barriers |pdf=|usr=}} | ||
| + | {{tp|p=32536693|t=2020. Antiviral Therapy during the Coronavirus Disease (COVID-19) Pandemic: Is It Appropriate to Treat Patients in the Absence of Significant Evidence?|pdf=|usr=011}} | ||
| + | {{tp|p=32487260|t=2020. Precision medicine for COVID-19: a call for better clinical trials.|pdf=|usr=011}} | ||
| + | {{ttp|p=32407539|t=2020. Clinical Trials for COVID-19: Can we Better Use the Short Window of Opportunity?|pdf=|usr=011}} | ||
| + | {{tp|p=32553502|t=2020. Ultrafast response of the French Society of Pharmacology and Therapeutics to the COVID-19 pandemic.|pdf=|usr=011}} | ||
| + | {{tp|p=32311763|t=2020. Off-Label Therapies for COVID-19-Are We All In This Together?|pdf=|usr=011}} | ||
| + | {{tp|p=32454982|t=2020. Amid COVID-19: the importance of developing an positive adverse drug reaction (ADR) and medical device incident (MDI) reporting culture for Global Health and public safety.|pdf=|usr=011}} | ||
| + | {{ttp|p=32539990|t=2020. A minimal common outcome measure set for COVID-19 clinical research.|pdf=|usr=011}} | ||
| + | {{tp|p=32575032|t=2020. Participation of more community hospitals in randomized trials of treatments for COVID-19 is needed.|pdf=|usr=011}} | ||
| + | |||
| + | {{tp|p=32583289|t=2020. Statistical Evaluation of Clinical Trials Under COVID-19 Pandemic.|pdf=|usr=011}} | ||
| + | {{tp|p=32557317|t=2020. New FDA Guidance on General Clinical Trial Conduct in the Era of COVID-19.|pdf=|usr=011}} | ||
| + | |||
| + | |||
| + | |||
| + | |||
| + | {{tp|p=32392494|t=2020. Sample sizes in COVID-19-related research.|pdf=|usr=011}} | ||
Aktuelle Version vom 8. Juli 2020, 14:13 Uhr
coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.
32562594 2020. Pregnant Women in Trials of COVID-19: A Critical Time to Consider Ethical Frameworks of Inclusion in Clinical Trials.
C7102592 ä. Core Outcome Set for Clinical Trials on Coronavirus Disease 2019 (COS-COVID)
32588335 2020. COVID-19, equipoise and observational studies: a reminder of forgotten issues.
32290293 2020. A Review of SARS-CoV-2 and the Ongoing Clinical Trials
32363333 ä. A real-time dashboard of clinical trials for COVID-19
32567239 2020. Advantages of Using Lotteries to Select Participants for High-Demand Covid-19 Treatment Trials.
| C7156793 2020. COVID-19 randomised trial protocols: rapid publication without barriers |
32292826 2020. A living systematic review protocol for COVID-19 clinical trial registrations
32566569 2020. Appealing for efficient, well organized clinical trials on COVID-19.
32245769 2020. Managing clinical trials for covid-19: the importance of ethics committees
32532425 2020. Inclusion of pregnant women in clinical trials of COVID-19 therapies: what have we learned?
32379296 2020. Inclusion of Children in Clinical Trials of Treatments for Coronavirus Disease 2019 (COVID-19)
32341581 2020. Antibody testing will enhance the power and accuracy of COVID-19-prevention trials
32179860 2020. Don t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees
32349053 ä. Protection by Exclusion: Another Missed Opportunity to Include Pregnant Women in Research During the Coronavirus Disease 2019 (COVID-19) Pandemic
32369865 2020. Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic
32333712 2020. SARS-CoV-2 pandemic and the need for transplant-oriented trials
32294824 2020. An urgent call for raising the scientific rigorousness of clinical trials on COVID-19
32610153 2020. COVID-19 trials in Italy: A call for simplicity, top standards and global pooling.
32292626 ä. Core Outcome Set for Clinical Trials on Coronavirus Disease 2019 (COS-COVID)
C7156793 2020. COVID-19 randomised trial protocols: rapid publication without barriers
32536693 2020. Antiviral Therapy during the Coronavirus Disease (COVID-19) Pandemic: Is It Appropriate to Treat Patients in the Absence of Significant Evidence?
32487260 2020. Precision medicine for COVID-19: a call for better clinical trials.
| 32407539 2020. Clinical Trials for COVID-19: Can we Better Use the Short Window of Opportunity? |
32553502 2020. Ultrafast response of the French Society of Pharmacology and Therapeutics to the COVID-19 pandemic.
32311763 2020. Off-Label Therapies for COVID-19-Are We All In This Together?
32454982 2020. Amid COVID-19: the importance of developing an positive adverse drug reaction (ADR) and medical device incident (MDI) reporting culture for Global Health and public safety.
| 32539990 2020. A minimal common outcome measure set for COVID-19 clinical research. |
32575032 2020. Participation of more community hospitals in randomized trials of treatments for COVID-19 is needed.
32583289 2020. Statistical Evaluation of Clinical Trials Under COVID-19 Pandemic.
32557317 2020. New FDA Guidance on General Clinical Trial Conduct in the Era of COVID-19.
32392494 2020. Sample sizes in COVID-19-related research.
